Several other cases of successful MEK-inhibitor use in MAP2K1-mutant malignancies have been documented, primarily non-Langerhans cell histiocytosis and hairy cell leukemia (Table 2) (30). This evidence concerns the gene MAP2K1 and Langerhans cell histiocytosis.